INM

Investor Moves

Name	Value	Action	Change	Price	Current Price
Jim SimonsRenaissance Technologies $-36.8K ExitQ4 2025 $37k -- $1.51
Ken GriffinCitadel Advisors $-13.3K ExitQ4 2024 $13k -- $1.51
Ken GriffinCitadel Advisors $-13.3K ExitQ4 2024 $13k -- $1.51
Jim SimonsRenaissance Technologies $-11.9K ExitQ4 2024 $12k -- $1.51
Jim SimonsRenaissance Technologies $-11.9K ExitQ4 2024 $12k -- $1.51
Ken GriffinCitadel Advisors $10.1K AddQ3 2024 $10k -- $1.51

Insider Trades

Name	Value	Action	Price	Current Price
Vivo Opportunity, LLC10 Percent Owner $3.2k2.1k shares BuyJun 2, 2026 $1.52 $1.51
Vivo Opportunity, LLC10 Percent Owner $2.6k1.6k shares BuyMay 29, 2026 $1.57 $1.51
Vivo Opportunity, LLC10 Percent Owner $2.3k1.5k shares BuyJun 1, 2026 $1.55 $1.51
Vivo Opportunity, LLC10 Percent Owner $1.1k714 shares BuyJun 3, 2026 $1.55 $1.51
Vivo Opportunity, LLC10 Percent Owner $80k51.1k shares BuyMay 20, 2026 $1.56 $1.51
Vivo Opportunity, LLC10 Percent Owner $52k30.9k shares BuyMay 21, 2026 $1.69 $1.51

News

prnewswire.comAre GBTG, INM, CZR, TMHC Obtaining Fair Deals for their Shareholders?prnewswire.comJun 12

newsfilecorp.comInMed Pharmaceuticals Regains Compliance with Nasdaq Continued Listing Requirementsnewsfilecorp.comJun 4

prnewswire.comAre RAMP, INM, D, NEE Obtaining Fair Deals for their Shareholders?prnewswire.comMay 28

gurufocus.comSHAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--RAMP, NEE, D, and INMgurufocus.comMay 28

globenewswire.com$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger—D, INM, ESQ, and GDOTglobenewswire.comMay 27

Trade INM

About InMed Pharmaceuticals Inc.

InMed Pharmaceuticals Inc. operates as a clinical-stage pharmaceutical firm, concentrating its efforts on the investigation and creation of therapeutic solutions derived from cannabinoids. Its primary product, INM-755, is a cannabinol-infused topical cream that is currently progressing through its second Phase I clinical trial for the management of epidermolysis bullosa. Beyond this lead candidate, the company is also developing INM-088, which is undergoing preclinical studies for glaucoma treatment, and INM-405, intended for pain relief. Its broader development pipeline encompasses cannabinoid-based interventions for a variety of medical conditions, with a particular focus on dermatological and ocular disorders. Furthermore, InMed is involved in critical IND-enabling pharmacology and preclinical toxicology research. It is also pioneering IntegraSyn, an innovative integrated biosynthesis approach designed to produce pharmaceutical-grade cannabinoids efficiently. The company maintains a research partnership with BayMedica Inc. to collaborate on the formulation and assessment of novel cannabinoid therapeutics. Established in 1981, the company is headquartered in Vancouver, Canada. It operated under the name Cannabis Technologies Inc. before officially rebranding as InMed Pharmaceuticals Inc. in October 2014.

CEO: Eric A. Adams Chem.
IPO Date: May 5, 2014

Market Data

Open: $1.52
High: $1.59
Low: $1.49
Volume: 23.1K
Avg Volume: 1.7M
52W High: $5.50
52W Low: $0.575

Valuation

Market Cap: $2.7M
Enterprise Value: $-2.0M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-7.8M
Revenue: $4.9M
Net Income: $-8.2M
Cash: $15M
Debt: $1.0M

Events

EarningsSep 18

EPS est. -94.44358